Asharq Al-Awsat Editorial

Editorial desk and wire-service reports (AFP, Reuters, AP) as published in the Asharq Al-Awsat English Edition. This archive preserves the original text (2005–2017); attribution appears in the article dateline where provided by the source.

54082 articles

Scientists Change Definition of the ‘Second’

London-What’s the length of a second? Scientists continue to ask themselves this question because no matter how accurately time is measured, there would still be an error of about a nanosecond every 30 days. Researchers in Germany said in a paper published in the journal Optica that the second becom

Washington Rejects to Negotiate on Anti-Hezbollah Law

Beirut-The U.S. assistant secretary for terrorist financing at the Treasury Department, Daniel Glaser, has informed Lebanese leaders about his country’s stance with regards to a law adopted by Congress that bans financial transactions with the so-called Hezbollah for being a terrorist group. Glaser

Gulf – Russian Agreement to Defeat Terrorism

Gulf countries and Russia have agreed to work together to prevent and avert terrorist acts through international cooperation, fully recognising the central role that the United Nations plays according to its charter and completely implementing the relevant Security Council resolutions, especially re

World

Revival of Oil Prices

The best news so far this year is that oil prices have risen reaching $50 and few cents per barrel. Prices were expected to continue declining to around $20, thus expanding the economic crisis and shaking not only petroleum-exporting countries but also the region. Moreover, this rise in the oil pric

China Faces Headaches from Warming Vietnam-U.S. Ties

The United States and Vietnam have complicated the strategic outlook for China over the disputed South China Sea. For instance, Obama’s last trip to Asia was remarkably highlighted by the historic lifting of Washington’s arms embargo on Vietnam, with the latter repeatedly insisting it was not

Roche Boosted by Trial Success with Blood Cancer Drug

Roche got a big boost on Friday following a successful clinical trial testing its new blood cancer drug, Gazyva, thus bracing visions for a new medicine that will be pivotal as the Swiss company fights the threat of biosimilar competition. Gazyva proved to be considerably better than its older drug